CTMX vs IT · rev $138.1M vs P/E 16, rev $6.27B
CytomX Therapeutics Inc (CTMX) versus Gartner Inc (IT) — a side-by-side from cached financials, not a winner call.
CytomX Therapeutics Inc (CTMX) is a biotechnology company listed on US.
Gartner Inc (IT) is a information technology services company listed on US.
Latest reported CTMX revenue for 2024-12-31 was $138.1M. Net income was $31.9M. Revenue was up 36.4% from 2023-12-31 to 2024-12-31. CTMX currently screens at market cap $653.1M.
Latest reported IT revenue for 2024-12-31 was $6.27B. Net income was $1.25B. Revenue was up 6.1% from 2023-12-31 to 2024-12-31. IT currently screens at market cap $11.03B and trailing P/E 16.3.
CTMX currently screens at market cap $653.1M. IT currently screens at market cap $11.03B and trailing P/E 16.3.
Not investment advice. Open the CTMX and IT stock pages for the full models.
Not investment advice.